Drug Trial Radar · NCT06239155
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Sep 3, 2019
Primary completion
Nov 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Ascentawits Pharmaceuticals, LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent
Conditions
- Advanced Solid Tumors
- Hepatocellular Carcinoma
Interventions
AST-3424Drug
liquid formulation for Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events(AEs)Time frame: measure begins from informed consent to 30 days after last dose of study drug.
- Safety changes in electrocardiogram (ECG)Time frame: Day 1 Cycles 1 and 2 (each cycle is 21 days)
- Safety Changes of body weightTime frame: Day 1 of each cycle (there are 34 cycles; 21 days for each cycle)
- Dose limiting toxicities (DLTs) in phase ITime frame: Throughout Cycle 1 (21 days for each cycle) in phase I (dose escalation phase).
- Maximum Tolerated Dose(MTD)/Recommended Phase 2 Dose (RP2D) in phase ITime frame: Day 1 and Day 8 of each cycle (all 34 cycles and there are 21 days for each cycle)
- Pharmacokinetics (PK) - Time to maximum concentration (Tmax)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
- PK - Maximum peak plasma concentration (Cmax)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
- PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
- PK - Half-life (T1/2)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
- PK - Area under the concentration-time curve (AUClast)Time frame: Days 1 and 8 of Cycle 1(first cycle of 34 cycles and there are 21 days for each cycle)
- Objective response rate(ORR)Time frame: Approximately 36 months
- Disease control rate(DCR)Time frame: Approximately 36 months
- Duration of response (DOR)Time frame: Approximately 36 months
- Progress free survival (PFS)Time frame: Approximately 36 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Guangdong Qifu Hospital
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Chinese People's Liberation Army Eastern Theater General Hospital Qinhuai medical District
Nanjing, Jiangsu, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.